Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps): Market View, Current and Future Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report provides a data-driven overview of the current and future competitive landscape in Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) Therapeutics.
In 2025, there were more than 5.15 million diagnosed incident cases of nasal polyps and CRSwNP in the 16 countries covered in GlobalData’s epidemiology forecast.
The current treatment landscape for nasal polyps primarily involves intranasal corticosteroids, oral corticosteroids for severe cases, and functional endoscopic sinus surgery for patients unresponsive to medical therapy, with biologics like Nucala and Tezspire now emerging as effective options and reducing the need for surgery and systemic steroids.
The nasal polyps and CRSwNP pipeline holds 33 molecules, with two assets (one biosimilar) in the pre-registration stage, nine assets in Phase III development, and another eight in Phase II.
Over the past decade, 269 clinical trials have been conducted in PBC. The year with the most studies initiated was 2025, with 37 trials, followed by 2023 with 33 trials.
Over the past decade, acquisitions accounted for the largest share of deals in North America (38.5%). Licensing agreements were the major deal type in Europe (46.7%), APAC (33.3%), Africa (66.6%), and South America (66.7%).
The consensus from PMR was that treatment approaches are broadly consistent worldwide, but biologics remain restricted to later lines in most markets outside the US following failure with first-line treatments/surgery.
Scope
GlobalData’s Diabetic Retinopathy: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule type
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Nasal Polyps (Nasal Polyposis) and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps) Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Nasal Polyps (Nasal Polyposis) reports